Tesamorelin before and after claims: what the trials actually show

Last updated 2026-07-25

What does tesamorelin actually do to body composition, according to trials?

Tesamorelin (brand name Egrifta) is a synthetic analogue of growth hormone releasing hormone. It works by stimulating the pituitary to release more of the body's own growth hormone, which in turn raises IGF-1 and, in people with HIV-associated lipodystrophy, reduces visceral adipose tissue (VAT) ^{[1] [2]}. The main evidence comes from a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials in HIV-infected patients with excess abdominal fat. Tesamorelin produced a statistically significant reduction in VAT compared to placebo, along with improvements in triglycerides and trunk fat, without a meaningful change in subcutaneous fat or body weight ^[3]. That's the actual dataset behind the drug's approval, and it's worth sitting with: this is a visceral fat drug, not a general weight-loss or muscle-building drug. A more recent meta-analysis of randomized controlled trials pooling this and later data confirms the pattern: tesamorelin reliably lowers VAT and improves some liver fat and metabolic markers in HIV-associated lipodystrophy, with a safety profile consistent across trials ^[3]. That consistency across multiple RCTs is why the evidence base here is unusually solid for a peptide, and why we treat it differently from most other compounds covered on this site.

How much visceral fat loss shows up in the before-and-after data?

In the core phase 3 program, tesamorelin reduced visceral adipose tissue by roughly 15-18% relative to baseline over 26 weeks, versus little to no change with placebo ^{[3] [4]}. That's the number behind most of the 'before and after' claims you'll see referenced, even when the person posting the photo never says where it came from. A separate analysis specifically looking at visceral fat reduction found it was associated with improved liver enzymes in the HIV population studied, suggesting the VAT drop isn't just cosmetic, it correlates with a metabolic signal too ^[5]. Another study using MRI-based fat quality assessment found tesamorelin improved fat quality (meaning the composition/density of fat tissue, a marker tied to metabolic risk) independent of the raw quantity change, in a controlled 2021 analysis ^[6]. Here's the honest caveat: waist circumference and visible midsection change in photos are influenced by subcutaneous fat, water retention, muscle tone, and even posture. None of the phase 3 trials found a significant change in subcutaneous fat or total body weight ^[3]. So a dramatic before/after photo showing a flatter stomach could reflect VAT loss, but it could also reflect something else entirely, like diet changes during the observation window that weren't controlled for in someone's personal use, unlike in the trial.

What was the FDA approval actually based on, and what indication does it cover?

Egrifta was approved by the FDA specifically for the reduction of excess visceral fat in HIV-infected patients with lipodystrophy. That is the entire scope of the approved indication. You can confirm active approval status and labeling history through Drugs@FDA [database link below] . Lipodystrophy itself is a defined clinical syndrome, more than 'stubborn belly fat.' A 2022 clinical review on diagnosing and managing lipodystrophy syndromes describes the abnormal, often disproportionate distribution of body fat (excess visceral fat combined with peripheral fat loss) seen in this population, frequently tied to antiretroviral therapy history ^[7]. A companion paper on diagnostic approach reinforces that lipodystrophy has specific clinical criteria, it isn't a synonym for general adiposity ^[8]. This matters for interpreting before/after claims. If someone without HIV or without diagnosed lipodystrophy shows dramatic photos, they are describing an off-label use case with no phase 3 trial behind it for that population. The approval halo doesn't transfer automatically.

Does tesamorelin work the same way in people without HIV?

Nobody has good phase 3 data on this. The approved trials, the ones that generated the before/after numbers everyone cites, enrolled HIV-positive patients with lipodystrophy specifically ^{[3] [4]}. A 2024 study looked at efficacy and safety of tesamorelin in people with HIV who were also on integrase inhibitors, a more modern antiretroviral regimen than what some of the original trials used, and found the drug's effects held up in that context ^[9]. But that's still an HIV population. Broader reviews of injectable peptide therapy in sports medicine and orthopaedic contexts describe growing off-label interest in GHRH analogues like tesamorelin for body composition goals outside the approved population, while noting the evidence for those uses is much thinner than for the approved indication ^{[1] [10]}. A recent review of approved and unapproved peptide therapies makes a similar point: enthusiasm in clinical and fitness settings is outpacing controlled trial evidence for many peptides, tesamorelin included when used outside its label ^[10]. If you're considering tesamorelin without HIV-associated lipodystrophy, understand you're relying on extrapolation, not a matching trial population. That's not necessarily a dealbreaker for a provider decision, but it should reset your expectations about how confidently anyone can predict your specific 'before and after.'

What else changes besides visceral fat, according to the trials?

Liver fat is the most studied secondary outcome. A randomized, double-blind, multicenter trial published in The Lancet HIV found tesamorelin reduced hepatic fat fraction and led to a higher proportion of participants achieving resolution of NAFLD (non-alcoholic fatty liver disease) compared to placebo over 12 months in people with HIV ^[11]. A companion mechanistic study used hepatic transcriptomic signatures to show tesamorelin altered gene expression patterns tied to fat metabolism in the liver in this population, offering a biological explanation for the imaging findings ^[12]. A related proteomic and transcriptomic analysis identified specific response pathways tied to how individual patients' NAFLD improved on tesamorelin, suggesting responses aren't perfectly uniform across patients ^[13]. Inflammatory markers also shift. A study measuring inflammatory markers alongside visceral fat reduction found the VAT decrease was linked to improvements in certain inflammatory biomarkers in the same HIV population , though this is a correlation within a specific trial population, not proof tesamorelin is an anti-inflammatory drug broadly. A more recent 2025 study examined whether tesamorelin affects neurocognitive function in people with HIV and abdominal obesity, an area of active investigation, since the HIV population has elevated rates of cognitive complaints tied to metabolic and inflammatory factors ^[14]. This line of research is newer and shouldn't be read as an established benefit; it's worth watching, not banking on.

How reliable are before-and-after photos as evidence?

Photos are the weakest form of evidence in this entire conversation, and it's worth saying plainly: a single photo pair proves almost nothing on its own. Lighting, posture, hydration, and even camera angle change how a midsection looks far more than most people realize. The trial data is stronger precisely because it used objective measurement, CT or MRI-based VAT quantification, not visual inspection ^{[3] [6]}. When you see a transformation photo online, ask what was actually measured. Was there a scan? A specific number? Or just a flatter-looking stomach after a few months that could be explained by a dozen other variables including diet, water weight, or camera choice. This doesn't mean visible change is fake. It means visible change alone can't tell you whether tesamorelin specifically caused it, especially outside a controlled trial where diet, activity, and other medications are tracked.

What's the difference between visceral fat loss and general weight loss here?

This is probably the single most misunderstood point in any tesamorelin before/after discussion. Visceral fat is the fat wrapped around internal organs; subcutaneous fat is the fat under the skin that you can pinch. Tesamorelin's trial evidence is specifically about the former. The pooled phase 3 analysis found no significant change in body weight and no significant change in subcutaneous fat, only VAT ^[3]. That means someone taking tesamorelin per the trial protocol might see very little difference on a bathroom scale, or even in their pinch test, while still experiencing meaningful VAT reduction. Conversely, someone who loses weight generally (through diet, exercise, or another drug) may see photo changes that look similar to a VAT responder's, without the same organ-level fat change happening underneath. If your goal is scale weight or a smaller pinch of belly fat, tesamorelin's trial evidence doesn't directly support that expectation. If your goal is reducing the fat around your organs, specifically in the context of HIV-associated lipodystrophy, that's what the approved trials measured.

What do the safety and side effect trends look like across the trial data?

Across the phase 3 program and safety extension data, the most commonly reported side effects were injection site reactions, and there were signals around glucose metabolism worth monitoring, consistent with a growth-hormone-axis mechanism ^{[3] [4]}. A 2026 meta-analysis of RCTs also reported on safety outcomes across the pooled trial data, generally finding a consistent adverse event profile without new major safety signals emerging when trials were combined ^[3]. A 2011 review in BioDrugs summarized the drug's mechanism and clinical trial safety findings in HIV-associated lipodystrophy specifically, describing it as generally well tolerated in that population with the expected GH-axis-related effects ^[15]. An Annals of Pharmacotherapy review from 2012 covers similar ground on tolerability and practical prescribing considerations ^[16]. None of this is a substitute for a real safety conversation with a prescriber about your own labs, especially glucose and IGF-1 levels, before and during use. For dosing specifics and injection logistics, see how to reconstitute tesamorelin and tesamorelin how to inject.

Does fat come back after stopping tesamorelin?

The core trials were structured around continued use, with safety extension data following patients further, but the phase 3 dataset behind the approval doesn't answer the maintenance question as cleanly as people assume ^{[3] [4]}. GHRH analogues work by stimulating an ongoing physiological process (pulsatile GH release); when you stop stimulating it, there's no mechanistic reason to expect the visceral fat reduction to be a permanent, absorbed structural change the way, say, surgical fat removal is. A broader review on growth hormone in the aging male discusses how GH axis effects on body composition generally depend on continued exposure, a relevant analogy even though that review isn't tesamorelin-specific ^[17]. This is consistent with how most people describe their own before/after experience anecdotally online, that gains made during a cycle tend to soften after stopping, though there's no controlled trial specifically measuring VAT rebound after tesamorelin discontinuation in the way there is for VAT reduction during use. If you're planning a course, it's worth reading about tesamorelin cycle length before you start, so your expectations about maintenance match the actual mechanism, more than the marketing.

How does tesamorelin's evidence compare to other GH-axis peptides people compare it to?

Tesamorelin is unusual in this space because it has actual phase 3, FDA-reviewed trial data behind a specific indication. Most other GH-releasing peptides marketed for body composition don't. A recent review covering approved and unapproved peptide therapies for musculoskeletal and athletic performance use draws this distinction directly, noting the gap between compounds with regulatory-grade evidence and those circulating with essentially no controlled human trial data ^[10]. | Feature | Tesamorelin (Egrifta) | Typical unapproved GHRH/GHRP peptides |

What should someone realistically expect from tesamorelin outside the approved indication?

Honestly, uncertainty is the accurate answer here. There is no phase 3 trial measuring VAT reduction, liver fat improvement, or any of the other endpoints in a general population without HIV-associated lipodystrophy. Extrapolating the 15-18% VAT reduction figure from the approved trials ^{[3] [4]} to a different population, different baseline body composition, and different metabolic context is a guess, not a documented outcome. A review on therapeutic peptides in aesthetic, metabolic, and endocrine conditions covers tesamorelin among other peptides being used for body composition and metabolic goals, and it's explicit that safety and efficacy data for many of these off-label applications remain limited compared to the approved-indication evidence ^[18]. That's a useful frame: the drug itself has strong data, the off-label use case usually doesn't have matching data yet. If you go this route with a provider, track objective markers (waist circumference measured consistently, labs, ideally imaging if accessible) rather than relying on photos alone, given everything above about how unreliable photo-based before/after claims are on their own.

How is tesamorelin sourced and does that affect what a before/after result actually means?

Egrifta is the FDA-approved, manufactured product. Compounded tesamorelin, made by a 503A or 503B pharmacy from bulk drug substance, is a different regulatory category. Bulk tesamorelin's compounding status is governed under 21 U.S.C. 353a and the associated bulk substance list maintained under 21 CFR 216.23 ^{[19] [20]}. Why does this matter for before/after claims specifically? Because a before/after photo attached to a compounded product doesn't necessarily reflect the same pharmacokinetic profile studied in the approved phase 3 trials. A 2015 population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects established dosing and exposure parameters specific to the studied formulation ^[21]. Sourcing quality and formulation consistency matter more than people assume when comparing your own results to trial data. If you're weighing where results come from and what you'd pay, see tesamorelin cost. Tesamorelin Co works with a provider-reviewed pathway and names its fulfilling pharmacy partner directly to buyers, rather than leaving sourcing as a black box, precisely because the gap between approved-product data and compounded-product reality is real and worth being transparent about.

What practical steps make your own before/after comparison more meaningful?

If you want your personal results to actually mean something, borrow from the trial methodology rather than relying on a mirror selfie. Measure waist circumference the same way, same time of day, same conditions, at baseline and at set intervals. If you have access to any imaging or a DEXA scan, a true visceral fat measurement is far more informative than a tape measure, since that's literally what the phase 3 trials tracked ^[3]. Track labs too, glucose and IGF-1 at minimum, since the trial safety data flagged the GH axis as the mechanism to monitor ^{[3] [3]}. Note your diet and activity level honestly during the period, since the main trials' VAT effect wasn't attributed to diet, but your personal experience won't have that same controlled isolation. And be realistic about timeline. The main trials measured outcomes at 26 weeks ^[3], not four weeks. If you're evaluating a 'before and after' at one month, you're not looking at a timeframe that matches the evidence at all. For dosing timing questions, see best time to take tesamorelin peptide and tesamorelin injection sites.

Frequently asked questions

How long does it take to see before-and-after results with tesamorelin?

The main phase 3 trials measured visceral fat reduction at 26 weeks (about 6 months) ^[1]. Some metabolic markers, like liver fat improvement, were tracked over 12 months in a separate trial ^[21]. Expecting dramatic visible change before 3-4 months isn't consistent with the timeline the approved trials actually used.

Does tesamorelin cause weight loss, based on the trial data?

No, not according to the main trials. The pooled phase 3 analysis found no significant change in total body weight, only in visceral adipose tissue specifically ^[1]. If someone's before/after shows major scale weight loss, that's likely from diet, exercise, or another intervention, not a documented tesamorelin trial effect.

Is tesamorelin FDA-approved for general fat loss or anti-aging use?

No. Egrifta is FDA-approved specifically for reducing excess visceral fat in HIV-infected patients with lipodystrophy ^[1][27]. Any use for general fat loss, bodybuilding, or anti-aging purposes is off-label and lacks the phase 3 trial evidence that supports the approved indication.

Why do some before-and-after photos look more dramatic than the trial data would suggest?

Photos are affected by lighting, posture, hydration, and camera angle far more than most people realize, and none of that was controlled in the phase 3 trials, which used CT/MRI-based measurement instead ^[1][15]. A dramatic photo could reflect real VAT change, unrelated diet change, or simply a better angle.

Does tesamorelin help with liver fat, more than belly fat?

Yes, in the studied HIV population. A randomized, double-blind trial found tesamorelin reduced hepatic fat fraction and increased NAFLD resolution rates compared to placebo over 12 months ^[21], with a companion mechanistic study describing gene expression changes tied to that effect ^[12].

Do tesamorelin results reverse after stopping treatment?

There's no controlled trial specifically measuring VAT rebound after stopping tesamorelin. Given the drug works by stimulating ongoing GH release rather than causing permanent structural change, there's no mechanistic reason to expect the visceral fat reduction to persist indefinitely without continued use ^[1][22].

Can tesamorelin before-and-after claims apply to people without HIV?

The trial evidence behind the 15-18% VAT reduction figure comes entirely from HIV-positive patients with lipodystrophy ^[1][20]. There's no matching phase 3 dataset for people without HIV, so before/after claims from that population are extrapolations, not documented trial outcomes.

What's the difference between visceral fat and subcutaneous fat in tesamorelin results?

Visceral fat surrounds internal organs and is what the phase 3 trials measured and reduced significantly. Subcutaneous fat, the kind you can pinch, showed no significant change in the main trials ^[1]. This is why some people don't see much difference in a pinch test despite real internal fat change.

Are there real photos or imaging from the tesamorelin phase 3 trials?

The trials used CT and MRI-based visceral adipose tissue quantification rather than photography as the primary outcome measure ^[1]. That's a meaningfully more objective standard than the before/after photos typically shared informally, which weren't part of the regulatory evidence base.

Does tesamorelin improve fat quality, more than fat quantity?

A 2021 controlled analysis found tesamorelin improved fat quality, a composition/density marker tied to metabolic risk, independent of changes in raw fat quantity ^[15]. This suggests some benefit may not show up as a dramatic size change even when a real tissue-level effect is happening.

What side effects show up alongside tesamorelin's body composition changes?

Injection site reactions were the most commonly reported issue across the main trials, along with glucose metabolism changes worth monitoring given the growth-hormone-axis mechanism ^[1][20]. A 2026 meta-analysis of RCTs found a consistent adverse event profile across pooled trial data without new major safety signals ^[17].

Is compounded tesamorelin the same as the FDA-approved Egrifta used in trials?

Not automatically. Egrifta is the FDA-approved manufactured product used in the phase 3 trials. Compounded versions are made under different regulatory pathways (21 U.S.C. 353a, with bulk substances tracked under 21 CFR 216.23) ^[8][10], and formulation consistency can differ from what was studied.

Sources

1. J Clin Endocrinol Metab (PMID 20554713): Pooled phase 3 trial analysis found tesamorelin significantly reduced visceral adipose tissue with no significant change in body weight or subcutaneous fat
2. Am J Sports Med, Injectable Peptide Therapy primer (PMID 41476424): Reviews GHRH analogues like tesamorelin among peptides used off-label in sports medicine, noting evidence gaps outside approved indications
3. Nature Reviews Drug Discovery, Tesamorelin (PMID 21283099): Describes tesamorelin's mechanism as a GHRH analogue stimulating pituitary GH release
4. Sports Medicine, Safety and Efficacy of Approved and Unapproved Peptide Therapies (PMID 41966639): Distinguishes peptides with regulatory-grade phase 3 evidence like tesamorelin from unapproved peptides lacking controlled trial data
5. AIDS, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (PMID 38905488): Tesamorelin's effects were studied and held up in HIV patients on integrase inhibitor-based antiretroviral regimens
6. J Infect Dis, Effects of Tesamorelin on Neurocognitive Impairment (PMID 39813152): 2025 study examined tesamorelin's effect on neurocognitive impairment in people with HIV and abdominal obesity
7. 21 U.S.C. 353a, pharmacy compounding: Federal statute governing pharmacy compounding under section 503A
8. Ann Pharmacother, Tesamorelin review (PMID 22298602): Reviews tesamorelin tolerability and practical prescribing considerations in HIV-associated lipodystrophy
9. JCI Insight, hepatic transcriptomic signatures (PMID 32701508): Tesamorelin altered hepatic gene expression patterns tied to fat metabolism in HIV-associated NAFLD
10. BioDrugs, Spotlight on tesamorelin (PMID 22050344): Summarizes tesamorelin's clinical trial safety findings in HIV-associated lipodystrophy as generally well tolerated
11. J Clin Endocrinol Metab, Approach to the Patient With Lipodystrophy (PMID 35137140): Describes lipodystrophy as a defined clinical syndrome with abnormal fat distribution, often linked to antiretroviral therapy history
12. AIDS, Tesamorelin improves fat quality (PMID 33756511): Tesamorelin improved fat quality independent of changes in fat quantity in a controlled analysis
13. Int J Mol Sci, Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions (PMID 42123471): Notes safety and efficacy data for off-label peptide body composition uses, including tesamorelin, remain limited compared to approved-indication evidence
14. Obesity Research & Clinical Practice, meta-analysis of RCTs (PMID 41545261): 2026 meta-analysis of RCTs found consistent VAT and liver fat improvements and a consistent safety profile across pooled tesamorelin trials
15. Scientific Reports, tesamorelin response pathways (PMID 34006921): Proteomic and transcriptomic analysis identified individual variation in patient response pathways to tesamorelin in NAFLD
16. AIDS, Visceral fat reduction improved liver enzymes (PMID 28832410): Visceral fat reduction with tesamorelin was associated with improved liver enzymes in HIV patients
17. Lancet HIV, tesamorelin and NAFLD (PMID 31611038): Randomized double-blind trial found tesamorelin reduced hepatic fat fraction and increased NAFLD resolution rates over 12 months versus placebo
18. Best Pract Res Clin Endocrinol Metab, Growth hormone in the aging male (PMID 24054930): GH axis effects on body composition generally depend on continued exposure to the stimulus
19. Clin Pharmacokinet, population PK analysis (PMID 25358450): Established population pharmacokinetic parameters for tesamorelin in HIV-infected patients and healthy subjects
20. Ann Endocrinol, How to diagnose a lipodystrophy syndrome (PMID 22748602): Lipodystrophy has specific clinical diagnostic criteria distinct from general adiposity
21. AIDS, inflammatory markers and visceral fat reduction (PMID 21516030): Tesamorelin-related visceral fat reduction was linked to improvements in certain inflammatory biomarkers in HIV patients
22. Drugs@FDA database: Egrifta's FDA approval and labeling history can be confirmed through the Drugs@FDA database
23. 21 CFR 216.23, 503A Bulks List: Federal regulation establishing the bulk drug substances list for 503A pharmacy compounding